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Abstract
Background: Pyrosequencing technology has the potential to rapidly sequence HIV-1 viral quasispecies without requiring
the traditional approach of cloning. In this study, we investigated the utility of ultra-deep pyrosequencing to characterize
genetic diversity of the HIV-1 gag quasispecies and assessed the possible contribution of pyrosequencing technology in
studying HIV-1 biology and evolution.
Methodology/Principal Findings: HIV-1 gag gene was amplified from 96 patients using nested PCR. The PCR products were
cloned and sequenced using capillary based Sanger fluorescent dideoxy termination sequencing. The same PCR products
were also directly sequenced using the 454 pyrosequencing technology. The two sequencing methods were evaluated for
their ability to characterize quasispecies variation, and to reveal sites under host immune pressure for their putative
functional significance. A total of 14,034 variations were identified by 454 pyrosequencing versus 3,632 variations by Sanger
clone-based (SCB) sequencing. 11,050 of these variations were detected only by pyrosequencing. These undetected
variations were located in the HIV-1 Gag region which is known to contain putative cytotoxic T lymphocyte (CTL) and
neutralizing antibody epitopes, and sites related to virus assembly and packaging. Analysis of the positively selected sites
derived by the two sequencing methods identified several differences. All of them were located within the CTL epitope
regions.
Conclusions/Significance: Ultra-deep pyrosequencing has proven to be a powerful tool for characterization of HIV-1
genetic diversity with enhanced sensitivity, efficiency, and accuracy. It also improved reliability of downstream evolutionary
and functional analysis of HIV-1 quasispecies.
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Introduction
Cloning of PCR products and subsequent Sanger dideoxy
sequencing have been widely used for the genetic analysis of HIV-
1, especially in estimating the diversity of quasispecies and
detecting mutations conferring antiretroviral drug resistance [1–
4]. However, this approach is time-consuming, labor-intensive,
and costly. Furthermore, polymerase induced sequence errors can
confound results when sequencing cloned DNA amplified by PCR.
More importantly, the number of clones that can be affordably
sequenced is unlikely to adequately represent the genetic variation
of the amplified viral population within a patient sample. Next-
generation sequencing technology (NGS) provides the potential to
greatly reduce the cost, complexity, and time required to sequence
DNA without the need for cloning [5–7]. NGS has been applied to
a broad range of applications to address diverse biological
problems, including genomic sequencing, transcriptome analysis,
and epigenome analysis [5,8]. For instance, the Roche 454
pyrosequencing (454) has been used in HIV research because of its
ability to provide long reads and ultra-deep coverage. Its
applications include identification of rare drug resistant variants
[9–15], prediction of HIV integration targets [16], estimation of
the diversity of genital microbiota in HIV-infected women [17],
and quantification of minor variants in co-receptor usage [9,18–
22], all of which are challenging by using Sanger clone-based
sequencing.
HIV demonstrates a higher degree of genetic variation than
other viruses because of the relatively low fidelity of its error-prone
reverse transcriptase [23] and the high turnover rate in replication
[24,25], features which have proven to be a major obstacle to
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26745vaccine development [26]. HIV diversity is shaped by a
combination of specific host-virus interactions [27–29], cell
tropism [30,31], immunological pressure [32–34], and functional
constrains on viral proteins [35,36]. Studying HIV sequence
variations derived from specific patient samples can provide
information on how the virus evolves and interacts with host, thus
helping to develop effective strategies to control HIV infection.
However, current applications of 454 in HIV research have mostly
focused on identification of rare drug resistant variants and
determination of cell tropism. There are not many studies
exploring the potential outcome differences while profiling the
HIV genetic diversity with different approaches and their
consequent impacts on downstream analysis.
In this study, we compared 454 pyrosequencing with SCB in
characterizing the genetic diversity of the HIV-1 gag quasispecies
from 96 patient samples and assessed the possible contribution of
pyrosequencing technology to commonly studied aspects of HIV-1
biology and evolution. We analyzed HIV-1 gag since HIV-1 Gag
proteins are under intensive selection pressure from host immune
responses, especially CTL responses, which are dominant in HIV-
1 virus control in the different clade infection[37,38]. Further-
more, the gag gene or proteins are also major components of HIV-
1 candidate vaccines currently in clinical trials [39].
Results
Characterization of 454 pyrosequencing data
An average of 8,031 sequence reads per sample was produced.
The generated consensus sequences of all 96 samples closely
matched those from Sanger sequencing. Twenty six samples had
low coverage (less than 100x) or dramatically inconsistent coverage
across the target sequence and were excluded from this study. For
the remaining 70 samples, 85.8% of 454 read sequences were
mapped to HIV-1 gag. The sequence coverage varied in different
regions of the HIV-1 gag gene, from a few hundred to over a
thousand with 384 sequence reads per nucleotide position
averaged over all samples (Figure S1). The details of variations
at each nucleotide are shown in Table S2.
Comparison of genetic variations generated by 454
pyrosequencing and SCB sequencing
SCB sequencing detected a total of 3,632 variations over the
1,503 nucleotides of the HIV-1 gag gene with an average of 53
variations per sample. By comparison, 454 pyrosequencing
detected 14,034 variations at an average of 204 variations per
sample (Table 1). The majority (11,050, 78.7%) of the variations
detected by 454 pyrosequencing were not detected by SCB
sequencing. Analysis of variation composition showed that only
33.2% (1205) of variations detected by SCB sequencing were
present at an abundance of ,20%. In contrast, 80.2% (11262) of
variations detected by the 454 pyrosequencing were present at an
abundance of ,20% (Table 1). For the minor variations only
detected by 454 pyrosequencing, 86% (9504) of them were present
at an abundance of ,10%. Within these 9504 variations, 4444
(46.8%) of them were non-synonymous mutations. Furthermore,
4215 minor variations at an abundance of ,2% identified by 454
pyrosequencing were not detected by SCB.
Impact of variations in detection of gag variations on
studying host virus interactions
Viral sequence variations generated by the error-prone reverse
transcriptase can be selected and maintained through interactions
with host immune responses as well as by functional constraints
[34,40,41]. The ultra-deep coverage of 454 pyrosequencing can
improve our understanding of viral-host interactions by reliably
elucidating dominant and subdominant variations of viral
quasispecies, which may not be identified by SCB sequencing.
We compared the non-synonymous variations from 454 pyrose-
quencing to those determined by SCB sequencing in terms of their
entropy scores at the known functional or immunogenic sites of
Gag proteins (CTL epitopes, proteasomal cleavage sites, neutral-
izing Ab epitopes, Ab epitopes and assembling & packaging sites of
virus), including the p17, p24, and p1p7p2p6. The difference in
entropy scores from two sets of protein sequences provides a
measure for the difference of composition of amino acids
generated from two sequence populations (454 and SCB) that
may be correlated to host immune responses. In this study, the
entropy scores at the functional or immunogenic sites of the p17
and p24 generated by the two methods are significantly different
(P=0.0273 and P=0.0302, respectively) (Table S1).
We also compared the consensus sequences derived from the
two viral sequence populations in each patient and estimated the
impact on studying the biology of HIV-1 Gag. We found that
there is a major difference in non-synonymous variations between
the two methods in 18 of 70 patients (25.7%) at 52 previously
determined functional or immunogenic sites of HIV-1 Gag
proteins (Table 2). Of them, 50% (26) are CTL epitopes and
34.6% (18) are neutralizing antibody epitopes. The rest (8, 15.4%)
includes 4 cyclophilin A binding sites, 2 virus particle formatting
sites, and 1 viral encapsulating site (Table 2).
Impact of the different variation detected by these two
sequencing platforms on studying the evolution of the
HIV-1 Gag gene
Viral sequence variation has been widely used to understand
HIV-1 evolution by predicting virus-host interaction to study host
Table 1. Comparison of the detected variations by 454 and Sanger Clone-based sequencing methods.
Method Total number of variations
a Average number of variations/per patient Minor variations
b only detected by 454 or Cloning
Total #
c
,20%
.20% .10%
,2%
2–10%
454 Sanger 14034
11262
2772 204
53
1546
4215
5289
3632
1205
2427 642
N/A
6
a: a variation is defined in this study as ‘a change’ in a nucleotide sequence (either a clonal Sanger sequence or a 454 read) compared to the consensus population-
based nucleotide sequence; b: a minor variation is defined as a nucleotide with an abundance less than 20% referred to the consensus population-based nucleotide
sequence; c: # represents number.
doi:10.1371/journal.pone.0026745.t001
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Patient ID
a Clade HLA type Position
b Sequence Function
c
ML1111 A1 N/A 086–115 YSVHQRIDVKDTKEALEKIEEEQN(N/K) KSKKKA(T/P) NEUTRALIZINGVIRUSES
N/A 121–132 DTGNSS(S/N)QVSQNY NEUTRALIZING VIRUSES
B*5703 162–169 K(K/R)AFS(N/S)PEVI CTL RESPONSES
B*5703 162–172 K(K/R)AFS(N/S)PEVIPMF CTL RESPONSES
B*4201 180–188 T(T/I)PQDLNTNL CTL RESPONSES
N/A 217–224 PVH(Q/H)AGPIA CYCLOPHILIN A BINDING
ML1857 C A*0201 077–085 SLY(Y/H)NT(T/A)VATL CTL RESPONSES
B*3501 254–262 PPI(V/I)PVGD(E/D)IY CTL RESPONSES
A*0201 433–442 FLGK(K/R)IWPS(P/S)Y(Y/H)K CTL RESPONSES
ML1992 A1 A*0801 074–082 EL(L/I)RSLYNTV CTL RESPONSES
A*3002 076–086 RSLY(F/Y)NTVATLY CTL RESPONSES
A*0201 077–085 SLY(F/Y)NTVATL CTL RESPONSES
N/A 086–115 YSVHQRIDVKDTKEALEKIEEE Q(Q/K)NKSKKKA NEUTRALIZING VIRUSES
N/A 113-122 KKAQQA(E/A)A(T/A)A(T/A)D(D/A)T NEUTRALIZING VIRUSES
N/A 121–132 D(D/A)TGH(S/N)SSQ(N/Q)VSQNY NEUTRALIZING VIRUSES
A*0801 329–337 DCK(K/R)TILKAL CTL RESPONSES
A*0201 433–442 FLGK(K/R)IWPSYK CTL RESPONSES
ML1876 A1 A*2602 028–036 KYKL(L/M)KHI(I/L)VW CTL RESPONSES
A*0202 077–085 SLY(Y/F)NTVATL CTL RESPONSES
N/A 113–122 KKAQQA(A/E)A(A/T)A(A/T)D(A/D)T NEUTRALIZING VIRUSES
N/A 121–132 D(A/D)TGH(S/N)SSQ(Q/N)VSQNY NEUTRALIZING VIRUSES
ML0795 A1 A*0202 077–085 SLYNTV(V/I)AT(T/V)L CTL RESPONSES
N/A 392–407 CFNC(C/Y)GKEGHLARNC VIRAL ENCAPSIDATION
ML1003 A1 B*5301 308–316 QASQE(D/E)VKN(N/C)W CTL RESPONSES
ML1102 D N/A 064 L(I/L)-.X PARTICLE FORMATION
N/A 113–121 KKAQQAA(T/A)ADT NEUTRALIZING VIRUSES
N/A 121–132 DTG(R/G)H(N/H)SSQVSQNY NEUTRALIZING VIRUSES
A*0201 433–442 FLGKIWPSY(H/Y)K CTL RESPONSES
ML1317 D A*0201 433–442 FLGKIWPSY(H/Y)K CTL RESPONSES
ML1208 A1 N/A 064 L(I/L)-.X PARTICLE FORMATION
A*0201 077–085 SLYNTVATL(L/I) CTL RESPONSES
N/A 121–132 DTGHSSQ(Q/K)VSQNY NEUTRALIZINGVIRUSES
ML1591 C A*0201 077–085 SLYNTVAT(T/V)L CTL RESPONSES
A*0201 433–442 FLGKIWPSY(N/H)K CTL RESPONSES
ML1660 D A*2402 028–036 KYK(K/R)LKHIVW CTL RESPONSES
N/A 086–115 YSVHQ(Q/E)R(R/K)ID(E/K)V(I/V)K(K/A)
DTKEALEKIEEEQN(N/T)KSKKKA
NEUTRALIZING VIRUSES
N/A 113–122 KKAQQAA(A/T)ADT NEUTRALIZINGVIRUSES
N/A 121–132 DTG(G/R)H(H/N)SSQVSQNY NEUTRALIZINGVIRUSES
ML1739 A1 N/A 113–122 KKAQQAAAD(D/G)T NEUTRALIZINGVIRUSE
ML0157 A1 A*0802 180–188 TPQDLNT(P/M)ML CTL RESPONSES
N/A 217–226 PVHAQPIA(A/P)P CYCLOPHILIN A BINDING
ML0415 A1 A*0301 020–028 RLRPGGKKK(K/Q) CTL RESPONSES
A*0301 020–029 RLRPGGKKK (K/Q) Y CTL RESPONSES
ML0548 A1 B*57 248 A(A/G)-.G B*57 ESCAPING[68]
ML1594 A1 N/A 017–022 EKIR(E/R)LR NEUTRALIZING VIRUSES
B*0801 024–032 GGK(R/K)KK(K/T)YK(K/R)L(M/L)K CTL RESPONSES
B*0801 074–082 ELRSLYNT(T/A)V CTL RESPONSES
N/A 121–132 DT(T/A)GH(H/S)SS(S/K)Q(K/Q)VSQNY NEUTRALIZING VIRUSES
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variations could influence the interpretation of host immune
responses on the HIV-1. We evaluated the ability of these two
methods at detecting positively selected amino acids, as one way to
study HIV-1 evolution. The majority of the patients were infected
by clade A1 (65.71%), with less than 35% by clade D (14.29%), C
(4.29%), B (4.29%), and recombinants (11.43%). The computa-
tional method, REL [42], was used to identify the amino acid
change under positive selection (PS) in HIV-1 Gag of clade A1 and
toevaluatewhetherthe resultsgeneratedbypyrosequencingorSCB
methods differ. Of the 42 positively selected (PS) amino acids
identified in the amplified sequence populations generated by the
two methods, 36 of these sites were identified by two methods.
However, 6 of these sites, including amino acid 107, 163, 219, 386,
436, and 441, were only identified in sequences by 454
pyrosequencing (Table 3). These 6 sites overlap with previously
identified CTLepitopes.A163Gisassociatedwith HLA classIallele
B*5703 and predicted to be an escape mutation that may interrupt
peptide processing of the 162KAFSPEVIPMF172 epitope [43].
Discussion
To understand the kinetics of HIV evolution in vivo, the
approach being used should be able to detect the HIV quasispecies
of low frequency. This is especially critical when the ‘‘minor’’
mutant population is of particular significance, such as in HIV
drug resistance or viral escape testing. In this respect, 454
pyrosequencing technology is superior than traditional SCB
method in its ability to generate a large amount of sequence data
in one instrument run to achieve hundreds fold coverage at ease.
Indeed, despite the large amount of data loss (67%) upon filtering
for quality (from 2,360,500 to 771,011 reads) and short read length
(,102 bps) in this study, an average of 384 fold coverage was
achieved to allow us to detect low abundant viral variations,
especially the variations at a frequency lower than 20%, which is a
challenge for SCB method. As expected, 11050 (out of 14,034)
variations can only be detected by 454 pyrosequencing, which are
3 times more than the total variations identified by SCB
sequencing. Moreover, the majority (80.2%) of these variations
detected by 454 pyrosequencing technologies were low abundance
variations (,20% in the amplified population). To achieve similar
coverage using the SCB approach, at least 384 clones will need to
be sequenced for each individual at a much higher cost and
workload. Furthermore, the cloning procedure could introduce
bias due to unintentionally selecting bigger bacterial colonies and
amplification bias towards dominant quasispecies.
Previous studies have shown that 454 pyrosequencing technol-
ogy can reliably detect rare variations at abundances as low as one
or two percent [13,44–46]. Our findings are consistent with these
reports. We validated the reliability of these low abundance
variations using statistical analysis based on the empirical
sequencing error estimated from the experiment. We have
validated 4215 variations generated by 454 pyrosequencing with
frequencies of less than 2%, which is impractical for SCB methods.
Thus, our study has provided additional validation of this
technology in detecting low abundant variations, especially for
the rare drug-resistant variations as previously reported
[10,11,13].
Alternative methods have been developed to detect very low
abundant variations (less than 1%) such as allele-specific
sequencing [47,48] and single-genome amplification
(SGA)[49,50]. Our previous study has showed that minor
variations with a prevalence of 0.29% could be identified in
pooled pyrosequencing [15]. In comparison with pyrosequencing,
however, alternative methods are more complex and labor
intensive. Moreover, allele-specific sequencing can only detect a
small number of rare variations or investigate a fraction of
interesting sequences [47,51,52]. The SGA method claims to be
able to accurately represent HIV-1 quasispecies and preclude Taq-
inducted artifacts, template switching-induced recombination,
unequal template amplification, and cloning bias which are
produced in Sanger cloning sequencing [49]. Taq-induced artifacts
and template switching-induced recombination have been report-
ed during pyrosequencing [13,44,45]. However, Taq-induced
sequence errors can be considerably reduced by the described
statistical method [13]. A probabilistic Bayesian approach has
been developed to identify and correct PCR derived recombina-
tion errors by detecting haplotypes and estimating their frequen-
cies using pyrosequencing data [53]. None the less, with a high
sensitivity and reliability of detecting sequence variations,
pyrosequencing represents a better alternative in characterizing
genetic diversity of HIV-1, especially in detecting minor variations
within an amplified viral population.
More importantly, this study first describes the difference in the
consensus sequences (each amino acid with frequency .50%)
generated by the two approaches. The consensus sequence
represents the dominant sequence in an infected individual and
is widely used for molecular biological and evolutionary studies of
HIV-1. The magnitude of the difference between the consensus
sequences generated by these two methods is big enough to affect
the biological analysis of HIV-1 Gag both at population and
individual levels. At the population level, we observed significant
differences of the entropy scores [54] on the functional or
immunogenic sites of p17 (P=0.0273) and p24 (P=0.0302),
suggesting that there exists a significant difference in amino acid
(AA) composition between two amplified sequence populations
within the previously identified functional or immunogenic sites of
HIV-1 Gag (Table S1). It is further supported at the individual
level that the consensuses generated by these two methods are
Patient ID
a Clade HLA type Position
b Sequence Function
c
N/A 217–225 PVH(P/H)AQPI(V/I)AP CYCLOPHILIN A BINDING
ML1654 A1 N/A 121–132 DT(A/T)GH(S/N)SS(K/S)Q(Q/K)VSQNY NEUTRALIZING VIRUSES
ML1768 A1 N/A 121–132 D(A/D)TGHSSQ(Q/K)V(V/I)SQNY NEUTRALIZING VIRUSES
N/A 217–225 PVHAGPI(I/A)AP CYCLOPHILIN A BINDING
a: patient IDs are from a cohort of the Pumwani Sex Worker in Nairobi, Kenya; b: positions are referred to HXB2 gag gene; c: CTL epitopes are derived from the best-
defined CTL epitope summary (HIV Molecular Immunology 2009, Los Alamos National Laboratory, USA). The differences between consensus sequences are shown in
bold.
doi:10.1371/journal.pone.0026745.t002
Table 2. Cont.
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a and Sanger clone-based sequences.
Codon 454 Sequences Sanger clone-based Sequences Difference
Bayes Factor
b PS
c Bayes Factor PS
015 177597 Yes 22717.3 Yes No
054 2.78668e+10 Yes 2.52247e+08 Yes No
061 20427.3 Yes 9701.84 Yes No
062 2708.76 Yes 835.661 Yes No
066 385327 Yes 443180 Yes No
069 203.289 Yes 292.117 Yes No
072 193.453 Yes 160.073 Yes No
075 9548.06 Yes 3559.12 Yes No
076 614542 Yes 168643 Yes No
107 173.957 Yes 69.796 No Yes
118 237.882 Yes 189.383 Yes No
122 193.159 Yes 195.056 Yes No
127 3.72494e+06 Yes 52014.3 Yes No
143 445.954 Yes 182.668 Yes No
146 630.075 Yes 440.031 Yes No
147 11040.5 Yes 4416.9 Yes No
163 113.622 Yes 62.0193 No Yes
219 105.812 Yes 9.04153 No Yes
223 2751.54 Yes 305.449 Yes No
243 1.94733e+07 Yes 4.36644e+06 Yes No
303 1.88333e+08 Yes 102877 Yes No
310 288.617 Yes 228.149 Yes No
315 4706.23 Yes 1870.08 Yes No
332 1758.17 Yes 670.471 Yes No
336 187.775 Yes 153.787 Yes No
339 1e+25 Yes 2.43507e+10 Yes No
370 356.917 Yes 130.182 Yes No
372 1785.45 Yes 1049.52 Yes No
373 105671 Yes 37326.1 Yes No
386 191.782 Yes 8.79191 No Yes
436 106.006 Yes 43.9758 No Yes
441 1165.93 Yes 96.7639 No Yes
462 1101.03 Yes 399.319 Yes No
466 1300.13 Yes 1012.5 Yes No
474 282428 Yes 76613.5 Yes No
478 250.849 Yes 197.548 Yes No
481 1628.94 Yes 872.868 Yes No
483 224051 Yes 92560.6 Yes No
486 35465.5 Yes 13427.5 Yes No
487 71719.4 Yes 60727.3 Yes No
497 3628.8 Yes 1602.01 Yes No
498 571.563 Yes 438.724 Yes No
Forty-six amino acid consensus sequences (subtype A1) from 454 and Sanger clone-based methods are subjected to positive selection analysis by random effect
likelihood (REL) method. The result of FEL analysis is given as Bayes factor and possibility of positive selection. The differences of positively selected sites identified
between two amplified sequence populations are shown in bold.
a: 454 pyrosequencing;
b: Bayes factor value (.100) is deemed as positive selection;
c: positive selection.
doi:10.1371/journal.pone.0026745.t003
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Gag consensus were found to overlap with known functional or
immunogenic sites involving viral replication, assembling, pack-
aging, CTL response, neutralizing antibody response, cyclophilin
A binding (Table 2), and 50% of the amino acid differences were
within CTL epitope regions [55,56]. Thus, sequence variations
between 454 pyrosequencing and SCB approaches could poten-
tially lead to different results. Since our analyses did not include
amino acid variations with frequency ,50%, especially minor
variations, in any given individual, the amino acid difference
generated by the two methods could be underestimated.
Moreover, the low abundant variations may play an important
role in the functionality of HIV-1 Gag. Studies have shown that
CTL epitopes with high functional avidity rapidly select for
escaping mutations, resulting in low abundant variations which
can be recognized by CTLs and elicit strong host immune
responses [57,58].
It is established that selection pressures exerted by host immune
responses shape the genetic variation of HIV-1[27,32,59–62].
Measuring and understanding the selection pressures is an
important part of evolutionary biology [34,63,64]. Current
methods measuring selection pressures are based on protein-
coding sequences. The difference in dominant variations gener-
ated by pyrosequencing and SCB methods could affect the
interpretation of positive selection within amplified viral popula-
tions. Analysis using the REL method at given amino acid
positions within the HIV-1 Gag proteins showed that the positive
selection on those sites appears different, especially at codon 107,
163, 219, 386, 436, and 441 (Table 3). For example, for sequences
generated by SCB approach, codon 163 was not identified as a
positively selected amino acid; while for sequences generated by
454-pyrosequencing technologies, codon 163 was indeed identified
as positively selected. Since codon 163 is within 62KAFSPE-
VIPMF172 epitope, the difference in detecting positive selection on
this site could mislead interpretation on viral interaction with the
host to characterize positive selections.
Current collections of HIV sequence data in NCBI and Los
Alamos HIV Sequence Database are all generated by Sanger
sequencing of PCR products or clones from PCR products. These
data has been widely used by research communities to study HIV-
1. Our study suggests that the sequences generated by SCB
method are biased towards sampling major variations in viral
quasispecies population, which might result in less accurate
profiling of HIV-1 genetic diversity and affect reliability of
downstream functional or evolutionary analysis (i.e. positive
selection). Pyrosequencing can provide much deeper sampling of
the HIV-1 variations of a viral quasispecies population and a more
comprehensive and accurate profiling of HIV-1 diversity.
Therefore, caution should be taken in interpreting the result of
SCB sequence analysis.
There was significant data loss resulting from poor quality reads
and short read length of the sequences generated by pyrosequenc-
ing technology in this study. The data loss was primarily due to the
early platform of sequencer, Genome Sequencer 20 (GS20),
reagents and more stringent screening criteria for the high quality
reads applied in this study besides its inherent shortcomings in
terms of data loss during the internal 454 quality control process of
reads. Despite these shortcomings, the throughput of 454 still
generates datasets sufficient for this type of study. Further, the
current 454 instruments (GS FLX) have substantially improved the
quality (99.997% accuracy), throughput (up to 700 Mb), and read
lengths (up to 700 bps). With these improvements, one can
sequence the full HIV-1 genome (,9 to 10 Kb) at 1000 fold
coverage from 70 patient samples in one instrument run.
However, even the best current pyrosequencing technology still
cannot produce sequence reads long enough to cover the full HIV-
1 genome ((,9 to 10 kb). The assembly of pyrosequencing reads
still depends on the availability of sequences generated by SCB
methods.
It should be noted that there may be a limitation in using
provirus instead of circulating virus in this study as not all proviral
sequences produce functional virus. Even with this limitation, the
use of proviral sequences in this study does not affect the
comparison of 454 pyrosequencing and SCB methods, as the same
starting material was used for both approaches.
In conclusion, Ultra-deep pyrosequencing has proven to be a
powerful and potentially superior to the SCB method in
characterizing genetic diversity of HIV-1 quasispecies, especially
for the detection of low abundance variations. These consensus
sequence differences observed between these methods could
potentially impact the inferences made in the common studies of
the function and evolution of the HIV-1 genome.
Materials and Methods
Subjects
The study population includes antiretroviral treatment-naı ¨ve
HIV-1 positive women with chronic infections enrolled in the
Pumwani Sex Worker cohort in Nairobi, Kenya. HLA class I
genes had been previously typed in all subjects [43]. Both the
ethics committees of the University of the Manitoba and Kenyatta
National Hospital approved this study. All patients provided
informed written consent for participation in this study.
PCR amplification, cloning and sequencing with Sanger
method
Proviral DNA was isolated using 1 million PBMCs from 96 HIV-
1 positive women and the gag was amplified using nested PCR with
2 rounds of amplification. The first round PCR primers, HIV1F
59-CTTCCCTGATTGGCAGAAY-39 and HIV1R 59-CAAAA-
ATTGGGCCTGAAAATCC-39, generates about 2,642 bps of
product, and the second round primers, HIV2F 59-AATCTC-
TAGCAGTGGCGCCCGAACAG-39 and HIV2R 59-TGGAT-
GGCCCAAAGGTTAAACAATGG-39, generates amplicons of
about 1,997 bps. The second round PCR amplicon products were
purified using the MultiscreenHTS PCR plate (Millipore Corpo-
ration) and then cloned using the TOPO TA cloning kit
(Invitrogen). BigDye Terminator v3.1 (Applied Biosystems) was
used to sequence gag with specific primers T7 59-TAATACGACT-
CACTATAGGG-39,T 35 9-ATTAACCCTCACTAAAGGGA-39,
(GSF1.6) GAGSEQF1.6 59GATAGAGGTAAAAGACACCAAG-
39 (277-298), (GSF2) GAGSEQF2 59-CAGCATTATCAGAAG-
GAGCCAC-39 (541-562), (GOR) GAGPCRRN 59-CTCCA-
ATTCCCCCTATCATTTTTGGTTTCC-39. Purified sequenc-
ing products were analyzed with an ABI 3100 Genetic Analyzer
(Applied Biosystems). Nucleotide sequences were assembled and
edited with Sequencher 4.8 (Genecodes Corp.). An average of 30
clones per patient was sequenced and sequences were submitted to
NCBI GenBank with accession numbers GQ429817-432774.
Pyrosequencing
Ultra-deep pyrosequencing was carried on the same second
round PCR amplicons as used in cloning with a Roche GS20
sequencer by the Genomics Core Facility at the National
Microbiology Laboratory, Public Health Agency of Canada,
Canada. Briefly, the purified 96 gag PCR products used above
were mechanically sheared, ligated to the adaptors, separately
loaded into lanes (one lane/per sample) of the picolitre plate and
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picolitre reactors followed by pyrosequencing. The pyrose-
quencing yielded 2,360,500 sequence reads, 37.6% of which
passed the default quality control, with an average read length
of 102 base pairs [454 raw data was submitted to NCBI
GenBank Short Read Archive (SRA) with the accession number
SRA009360]. As the original PCR products may contain
human or microbial DNA, non-HIV contaminant reads were
filtered out by BLAST [65] alignment to the HIV-1 HXB2
reference sequence, resulting in 771,011 read sequences
remaining for this study.
Sequence alignment and determination of variations
The sequences of clones from each patient were aligned to the
HIV-1 HXB2 gag gene by ClustalW [66]. The variations and
their abundances in each sequence pool were identified by
comparing the sequence of each clone to the consensus of the
pool. The pyrosequencing reads from each patient were mapped
onto the corresponding multiple aligned Sanger clone sequences
by WUBLAST V2.0 [http://blast.wustl.edu/]. The abundance
of nucleotides or amino acids at each position was calculated
against the consensus sequence at each individual using Perl
scripts developed in-house (available from the author on request).
A variation was determined if there is ‘a change’ in a nucleotide
sequence (either a clone or a read) comparing to the consensus
sequence in each individual and its abundance was less than 50%
in the amplified sequence population. Minor variations, defined
as variations with an abundance of less than 20%, including ,5%
and ,%1, were filtered using the reported statistical methods
[13]. In this method, empirically observed distribution of error
rate was applied to discriminate sequence errors from authentic
variations on the assumption that the abundance of variation
follows a Poisson distribution. Only variations with their
abundances yielding a P-value of ,0.001 were considered to be
authentic [13].
Measure of amino acid variability and determination of
correlation between amino acid variation and HIV-1 Gag
function
Entropy scores were calculated for each position in the multiple
alignment for both the 454 and Sanger cloning amino acid
sequences as previously described [67]. The sequence population
consists of amino acid consensus sequences (one/per patient)
generated by either 454 pyrosequencing or SCB method. The
entropy scores from two amplified sequence populations and the
paired entropy differences from the two amplified sequence
populations were tested for normality using the Kolomogorov-
Smirnov test. After confirmation of normality, a Student’s t-test
was applied to compare entropy scores (calculated from functional
or immunogenic sites within HIV-1 Gag p17 and p24) of
sequences generated using 454 pyrosequencing and SCB methods.
The functional or immunogenic sites were defined as the amino
acids overlapping previously described optimal CTL epitopes,
neutralizing antibody epitopes, viral replication sites, and virus
particle formation sites (HIV Molecular Immunology 2009, Los
Alamos National Laboratory, USA).
Mapping of consensus differences to HIV-1 Gag
functional or immunogenic sites and positive selection
analysis
The amino acid consensus differences were first determined by
comparing the consensus sequences generated from each patient
by the two sequencing methods and then mapped to the HIV-1
HXB2 Gag reference. The consensus differences overlapping
HIV-1 Gag functional or immunogenic sites were determined. As
phylogenies cannot be generated from random shotgun pyrose-
quencing data for quasispecies within each individual, we
performed the PS analysis at the population level using the
consensus sequences from each individual. RIP software (http://
www.hiv.lanl.gov/content/sequence/RIP/RIP.html) was used to
detect recombination between different viral subtypes of the
sequences used in this study. Positive selection analysis was
conducted on 46 subtype A1 consensus sequences (subtype A1)
generated from the two sequencing methods using random-
effects likelihood (REL) [42,64]. The optimal time reversible
substitution model was first determined for the applied sequence
data and the maximum likelihood-based analysis was then
carried out.
Supporting Information
Figure S1 The 454 read coverage at each nucleotide
position of HIV-1 gag gene. The 454 read coverage at each
nucleotide position of HIV-1 gag gene was plotted for each
patient. Gag nucleotide sequence positions are referred to HXB2.
The average coverage of 454 reads among all the patients was
highlighted in bold.
(TIF)
Table S1 The entropy
a differences on functional and
immunogenic sites
b of HIV-1 Gag proteins between 454
and Sanger cloning amino acid sequences. a: Shannon
entropy is calculated as a measure of variations in protein
sequence alignments based on the method online (http://www.
hiv.lanl.gov/content/sequence/ENTROPY/entropy_one.html);
b: Gag protein functional and immunogenic sites are referred to
HIV Sequence Databases and HIV Immunology Database (Los
Alamos National Laboratory, USA); c: Paired Student t test was
conducted. P value with significance is highlighted. df: degrees of
freedom; CI: confidence interval.
(DOC)
Table S2 The 454 read coverage and corresponding
variation at individual level. The 454 read coverage and its
corresponding variation at each nucleotide position of HIV-1 gag
gene were shown for each patient. Gag nucleotide sequence
positions are referred to HXB2. p: represents patient; coverage:
454 read coverage at each nucleotide position of HIV-1 gag
gene.
(XLS)
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